SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Munch-a-Biotech Today
An SI Board Since December 1998
Posts SubjectMarks Bans
3158 136 0
Emcee:  Biomaven Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2408Qiagen munches Digene. Somewhat OT as this is a biotech tool company taking outtuck-6/3/2007
2407Genzyme will buy its cancer drug partner By Stephen Heuser, Globe Staff | May Icebrg-5/31/2007
2406Bradley Pharmaceuticals (BDY) up 22% on offer to be taken private by CEO. Compatuck-5/29/2007
2405>>Genzyme to Acquire Bioenvision for $345M Tuesday May 29, 9:55 am ET Genztuck-5/29/2007
2404congratulations, you are the recipient of the ignore feature.Casaubon-5/21/2007
2403A comment in Monday's Barron's: "The impetus for more consolidatiokeokalani'nui-5/20/2007
2402Inverness Sweetens Offer for Biosite By JON KAMP May 10, 2007 4:22 p.m. [WSJ] Doc Bones-5/14/2007
2401GENEVA, May 13 (Reuters) - Merck & Co. Inc. (MRK.N: Quote, Profile , ResearcIcebrg-5/13/2007
2400Noveko! tsx-v eko Read up on this company that is holding probably an unlimited noveko-5/13/2007
2399Mylan Acquires Generics Business of Merck KGaA for $6.7B in Cash: investorshub.DewDiligence_on_SI-5/13/2007
2398Did AZN know about this story when it bid for MEDI ? timesonline.co.uknigel bates-5/10/2007
2397>>7:11AM Shire Pharm says Vyvanse receives final DEA schedule classificatituck-5/3/2007
2396"Their last write up was only a week ago, no mention of management problemsJohn Metcalf-4/26/2007
2395Yes, that is odd. Their last write up was only a week ago, no mention of managemtom pope-4/26/2007
2394I don't think MOGN should be characterized as mismanaged. Rather, the opposiIcebrg-4/26/2007
2393Merrill's candidates: Cash Flow, Mismanagement & Biologics MedImmune istom pope-4/26/2007
239212:42PM Sciele Pharma to acquire Alliant Pharmaceuticals (SCRX) 24.58 +0.07 : CoIan@SI-4/24/2007
2391MedImmune Offer Comes In High: AstraZeneca To Pay $15.2 Billion By Jim Shrine Icebrg-4/24/2007
2390Also agreed bids tend to be the rule in biotech, as you want to hang on to the knigel bates-4/23/2007
2389Makes sense. Thanks.FiloF-4/23/2007
2388<i>does that basically mean that there is no chance for additional hagglinDewDiligence_on_SI-4/23/2007
2387Dumb question for the board: This was described as an auction with four pharmasFiloF-4/23/2007
2386<i>AstraZeneca Near The Purchase Of MedImmune</i> It’s official: inDewDiligence_on_SI-4/23/2007
2385AstraZeneca PLC Near The Purchase Of MedImmune Message 23483427sim1-4/23/2007
2384Let's make a deal Washington Business Journal - April 20, 2007 by Vandana Sisim1-4/21/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News